Haemonetics (HAE) Operating Income (2009 - 2026)

Haemonetics' Operating Income history runs 18 years deep, the most recent figure standing at -$23.0 million for Q1 2026.

• In Q1 2026, Operating Income fell 132.28% year-over-year to -$23.0 million; the TTM figure through Mar 2026 stood at $156.7 million (down 29.34% YoY), while the FY2026 annual figure was $156.7 million, down 29.34% from the prior year.
• Operating Income was -$23.0 million for Q1 2026 at Haemonetics, down from $67.4 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $71.3 million in Q1 2025 to a low of -$23.0 million in Q1 2026.
• Historically, Operating Income has averaged $41.9 million across 5 years, with a median of $44.6 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Operating Income soared 2113.45% in 2022, then slumped 132.28% in 2026.
• A 5-year view of Operating Income shows it stood at $43.3 million in 2022, then advanced by 6.24% to $46.0 million in 2023, then increased by 28.39% to $59.0 million in 2024, then advanced by 14.17% to $67.4 million in 2025, then plunged by 134.16% to -$23.0 million in 2026.
• The last three Operating Income figures came in at -$23.0 million (Q1 2026), $67.4 million (Q4 2025), and $58.5 million (Q3 2025), per Business Quant data.